Results 31 to 40 of about 44,644 (146)

New Spontaneous Model of Fibrodysplasia Ossificans Progressiva [PDF]

, 2008
We report the first known example of spontaneous, naturally occurring fibrodysplasia ossificans progressiva (FOP) in a mammal. The Southeast Asian mouse deer of the genus _Tragulus_ (Artiodactyla: Tragulidae) have an osseous sheath covering the lower ...
Robert Timm, Bruce Rothschild, Larry Martin   +2 more
core  

Insights into the biology of fibrodysplasia ossificans progressiva using patient-derived induced pluripotent stem cells

Regenerative Therapy, 2019
The demand for development of new drugs remains on the upward trend because of the large number of patients suffering from intractable diseases for which effective treatment has not been established yet.
Taiki Nakajima, Makoto Ikeya
doaj   +1 more source

Peripheral targets for neuropathic pain

British Journal of Pharmacology, EarlyView.
Neuropathic pain represents a significant clinical challenge, with still limited pharmacological approaches to symptomatic relief. This review focuses on molecular targets implicated in neuropathic pain, particularly those involved in peripheral mechanisms. Using the IUPHAR/BPS database of biological targets, their occurrence together with ‘neuropathic
Amirhossein Afsharipour, Cosmin I. Ciotu, Felix J. Resch, Michael J. M. Fischer   +3 more
wiley   +1 more source

Recent Topics in Fibrodysplasia Ossificans Progressiva [PDF]

Endocrinology and Metabolism, 2018
Fibrodysplasia ossificans progressiva (FOP) is a rare genetic disease that is characterized by the formation of heterotopic bone tissues in soft tissues, such as skeletal muscle, ligament, and tendon.
Takenobu Katagiri, Sho Tsukamoto, Yutaka Nakachi, Mai Kuratani   +3 more
doaj   +1 more source

In Vivo Base Editing Partially Rescues Bone Dysplasia in a Mouse Model of Hutchinson‐Gilford Progeria Syndrome

Aging Cell, Volume 25, Issue 9, September 2026.
Hutchinson‐Gilford progeria syndrome (HGPS) is a premature aging disorder caused by a mutation in LMNA that produces the toxic progerin protein. In this study, an adenine base editor delivered via AAV9 achieved partial gene correction in HGPS mice when given at two weeks of age, partially rescuing bone structural and gene expression parameters and ...
Wayne A. Cabral, Caleb M. Grenko, Diana Yeritsyan, Indeevar Beeram, Shubham Laiwala, Lukas R. Johnson, Urraca L. Tavarez, Tingfen Yan, Stephen M. Wincovitch, Luke W. Koblan, Xin D. Gao, Meirui An, Narisu Narisu, Leslie G. Biesecker, David R. Liu, Ara Nazarian, Francis S. Collins, Michael R. Erdos   +17 more
wiley   +1 more source

Unexpected Promotion of Bone Regeneration by Inhibition of BMPR1A‐Mediated BMP Signalling

Cell Proliferation, Volume 59, Issue 8, August 2026.
BMPR1A downregulation reduces ID1, releases TCF3 to activate GNG4‐PI3K‐AKT signalling, thereby promoting OPC proliferation and bone regeneration. ABSTRACT Bone morphogenetic protein (BMP) signalling plays a pivotal role in bone regeneration by regulating osteoprogenitor cell (OPC) function, and BMPs have been widely used in clinical treatment. However,
Zihao Zhou, Yun Zhai, Xiaochen Liu, Jiaojiao Shao, Jiani Zhou, Zhaoyang Li, Jiale He, Shuxian Lin, Qi Zhang   +8 more
wiley   +1 more source

Response to comment on 'Palovarotene reduces heterotopic ossification in juvenile FOP mice but exhibits pronounced skeletal toxicity'

eLife, 2019
We respond to concerns expressed by Pacifici and Shore (2019) about a recent paper (Lees-Shepard and Goldhamer, 2018a) in which we reported that the drug palovarotene can have severe side effects in a mouse model of fibrodysplasia ossificans progressiva.
David J Goldhamer, John B Lees-Shepard
doaj   +1 more source

Fibrodysplasia Ossificans Progressiva - An Uncommon Cause of Trismus

Indian Journal of Physical Medicine & Rehabilitation, 2022
Fibrodysplasia ossificans progressiva (FOP) is a progressively disabling genetic disorder. It is characterised by development of a secondary skeleton due to progressive hypertrophic ossification.
Ravi Sankaran, Sheela Nampoothiri, Abhishek Bhaskaran   +2 more
doaj   +1 more source

Effects of Renal and Hepatic Impairment on the Pharmacokinetics of Zilurgisertib

British Journal of Clinical Pharmacology, Volume 92, Issue 5, Page 1339-1351, May 2026.
Aim Small‐molecule activin receptor‐like kinase‐2 inhibitor zilurgisertib (INCB000928) is under investigation in a pivotal trial for the treatment of fibrodysplasia ossificans progressiva (FOP), an ultrarare genetic condition. This analysis assessed effects of renal and hepatic impairment on zilurgisertib pharmacokinetics.
Yan‐ou Yang, Yunlan Fang, Phillip Wang, Xiang Liu, Jay Getsy, Kevin Rockich   +5 more
wiley   +1 more source

Early stage fibrodysplasia ossificans progressiva: A case report

Radiology Case Reports, 2020
Fibrodysplasia ossificans progressiva is a very rare autosomal dominant genetic connective tissue disease with a progressive ectopic ossification of muscle (intramuscular) or perimuscular connective tissue such as tendons or joint capsules.
Achmad Fauzi Kamal, MD,PhD, Dina Aprilya, MD   +1 more
doaj   +1 more source